Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryCigna Upneeq Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0088

    Upneeq

    Customize your policy alerts

    Sign up for Cigna Policy IP0088 alerts

    Get alerted when Policy IP0088 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage determinations for Upneeq (oxymetazoline hydrochloride 0.1% ophthalmic solution) under Cigna-administered health benefit plans and applies to providers, subject to the member's benefit plan, applicable laws, and individual clinical circumstances.

    Policy Summary
    PayerCigna
    PolicyUpneeq
    Policy CodePolicy IP0088
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewDec 15, 2025
    Next Review DateN/A
    Key ActionSubmit Upneeq claims only for covered conditions and with applicable covered codes.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage language was added stating that Upneeq is experimental, investigational, or unproven for blepharoptosis or conjunctivitis because of insufficient data establishing safety, efficacy, and improved health outcomes.

    The policy wording for cosmetic use was revised to identify Upneeq use for blepharoptosis without functional limitation as not medically necessary.

    The revision history states that no criteria changes were made in the subsequent policy updates.

    2Published randomized Phase 3 studies
    304Patients in cited pooled studies
    42 daysStudy duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Conditions specifically not covered
    0.1%Solution concentration

    Coverage Criteria

    Conditions Not Covered

    Upneeq is considered experimental, investigational, or unproven for any condition, regardless of U.S. Food and Drug Administration (FDA) approval status, because sufficient data establishing safety, efficacy, and improved health outcomes are lacking.

    Specified noncovered conditions

    • Blepharoptosis: approval of Upneeq for treatment is not recommended because clinical efficacy data are insufficient; the clinical meaningfulness of observed changes is unclear, long-term efficacy data are unavailable, and Upneeq's role in management is not established.

      The policy specifically addresses acquired blepharoptosis with superior visual field deficit.

    • Conjunctivitis: oxymetazoline hydrochloride 0.1% ophthalmic solution has not been evaluated for this condition.

    Not Medically Necessary

    Upneeq is considered not medically necessary for the following use:

    Cosmetic use of Upneeq, including use for blepharoptosis when functional limitation is absent, is excluded from pharmacy benefit coverage.

    Cosmetic uses of Upneeq, including blepharoptosis when functional limitation is absent, are excluded from pharmacy benefit coverage.

    Use of Upneeq for cosmetic blepharoptosis without functional limitation is excluded as not medically necessary.

    Upneeq is considered not medically necessary for cosmetic uses, including blepharoptosis when functional limitation is absent.

    The policy states that oxymetazoline hydrochloride 0.1% ophthalmic solution (Upneeq) is considered not medically necessary for a condition identified in the coverage criteria.

    Cosmetic blepharoptosis without functional limitation is considered not medically necessary when treated with Upneeq.

    Provider and Billing Actions

    Billing Rule

    Use Applicable Covered Codes and Diagnoses

    Submit Upneeq claims only with the applicable covered procedure or drug codes and diagnosis support required by the policy. Claims billed for noncovered conditions, without applicable covered codes, or without supporting diagnosis information may be denied as not covered.

    • Use the most appropriate codes in effect on the submission date.
    • Confirm that the billed condition and diagnosis are covered under the applicable policy.
    Denial Risk

    Unproven or Noncovered Indications

    Upneeq is considered experimental, investigational, or unproven for specified conditions and any other condition when insufficient data establish safety, efficacy, and improved health outcomes, regardless of FDA approval status. Claims for these uses may be denied.

    Clinical Background

    Upneeq is oxymetazoline hydrochloride 0.1% ophthalmic solution. The policy discusses two randomized, double-masked, placebo-controlled Phase 3 studies in patients with acquired blepharoptosis and superior visual field deficits. Although the studies reported statistically significant improvements in superior visual field testing and marginal reflex distance, the policy notes that the clinical meaningfulness and long-term efficacy remain uncertain. Upneeq has not been evaluated for conjunctivitis.

    Clinical Definitions

    Marginal Reflex Distance 1 (MRD1)
    DefinitionThe distance between the center of the papillary light reflex and the upper eyelid margin.
    Measurement positionMeasured with the eye in primary gaze.
    Policy contextUsed as a secondary endpoint to assess change from baseline in patients with blepharoptosis.
    Leicester Peripheral Field Test (LPFT)
    DefinitionA test that assesses superior visual field deficits associated with ptosis.
    MeasurementMeasures the number of points seen in the top four rows.
    Policy context
    Policy Summary
    PayerCigna
    PolicyUpneeq
    Policy CodePolicy IP0088
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewDec 15, 2025
    Next Review DateN/A
    Key ActionSubmit Upneeq claims only for covered conditions and with applicable covered codes.
    SourceLink
    On This Page
    Coverage CriteriaProvider and Billing ActionsClinical BackgroundClinical Definitions
    • Blepharoptosis
    • Conjunctivitis
    • Other conditions not supported by sufficient evidence
    Denial Risk

    Cosmetic Use Is Not Covered

    Upneeq is not medically necessary for cosmetic uses. Cosmetic use includes treatment of blepharoptosis when functional limitation is absent, and is excluded from pharmacy benefit coverage.

    • Do not submit cosmetic Upneeq use as a covered medically necessary service.
    • Blepharoptosis without functional limitation is considered cosmetic.
    Denial Risk

    Unproven Blepharoptosis or Conjunctivitis Use

    Do not bill Upneeq for blepharoptosis or conjunctivitis as a covered indication. The policy considers these uses experimental, investigational, or unproven because available evidence is insufficient to establish clinically meaningful benefit and appropriate outcomes.

    • Blepharoptosis
    • Conjunctivitis
    Documentation Required

    Document Functional Limitation

    Before submitting a claim for Upneeq for blepharoptosis, document a covered functional limitation. Use without functional limitation is cosmetic, not medically necessary, excluded from pharmacy benefit coverage, and may be denied.

    • Verify and document functional limitation when applicable.
    • Do not submit cosmetic blepharoptosis use without functional limitation as covered treatment.
    The cited studies assessed change from baseline on Day 1, 6 hours after instillation, and Day 14, 2 hours after instillation.
    Blepharoptosis
    DefinitionAbnormal drooping of one or both upper eyelids.
    FormsBlepharoptosis may be congenital or acquired.
    Acquired formAcquired blepharoptosis can occur at any age but is most commonly seen in older adults.
    Upneeq
    MedicationOxymetazoline hydrochloride 0.1% ophthalmic solution.
    Drug classAlpha-adrenergic agonist.
    IndicationIndicated for the treatment of acquired blepharoptosis in adults.